UNSPSC 51111640: Masoprocol

This classification denotes a lipooxygenase inhibitor and antioxidant with the molecular formula C18H22O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7BO8G1BYQU, chemically known as 1,2-benzenediol, 4,4-(2,3-dimethyl-1,4-butanediyl)bis-, (r*,s*)- but generally known as masoprocol, which bears US NIH Compound Identifier 71398. European Medicines Agency schedules Masoprocol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08652MIG.

UNSPSC 51111640 Masoprocol, a Commodity code, covers pharmaceutical products supplied through state and local health programs, as evidenced by recent procurement activity focused on direct-to-manufacturer prescription fulfillment models. State and local governments buying under this code are primarily state health agencies managing pharmacy benefit programs for employees, retirees, and covered populations. The work being solicited involves establishing vendor capacity to supply pharmaceutical products through alternative distribution channels that bypass traditional pharmacy benefit managers, group purchasing organizations, and wholesalers — specifically, direct contracting arrangements between state agencies and manufacturers to improve prescription fulfillment efficiency and cost management. Vendors must demonstrate experience with direct contracting for self-insured employers and government health plans, flexibility to negotiate net pricing without rebates, and capability to implement value-based or outcomes-based agreements.

The Texas Health and Human Services Commission posted Request for Information No. HHS0017013 on April 3, 2026, seeking vendor capabilities and market intelligence regarding a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. The RFI, issued as a preliminary information-gathering mechanism rather than a formal competitive solicitation, invites responses from vendors interested in establishing direct supply relationships to support the state's pharmacy benefit objectives. No award values, budget ranges, or response deadlines for formal proposal submission have been identified at this stage; the state is conducting foundational research on available solutions and vendor capabilities to inform future procurement strategy before issuing a formal RFP with established financial and temporal parameters.